Adebrelimab
Based on 1 Customer Validation
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.06%
- CAS 番号: 2247114-85-6
- 分子量:145.56 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Human IgG4 kappa
Human
B7-H1/PD-L1/CD274
Adebrelimab (SHR-1316; 0.06-1mg/mL; 48 hours) inhibits effects on the cell proliferation, migration, invasion of SK-BR-3 and AU565 cells[1].
Adebrelimab (SHR-1316; 0.1-1mg/mL; 48 hours) downregulateds the expression of PD-L1, p-PI3K, p-AKT and upregulates the expression FOXO1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SK-BR-3 and AU565 cells
-
Concentration:0.06 mg/mL, 0.13 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL
-
Incubation Time:48 hours
-
Result:The viability of SK-BR-3 and AU565 cells decreased gradually.
-
Cell Line:SK-BR-3 and AU565 cells
-
Concentration:0.1 mg/mL, 1 mg/mL
-
Incubation Time:48 hours
-
Result:Promoted cell apoptosis.
-
Cell Line:SK-BR-3 and AU565 cells
-
Concentration:0.1 mg/mL, 1 mg/mL
-
Incubation Time:48 hours
-
Result:Decreased the migration rate of SK-BR -3 and AU565 cells.
-
Cell Line:SK-BR-3 and AU565 cells
-
Concentration:0.1 mg/mL, 1 mg/mL
-
Incubation Time:48 hours
-
Result:Downregulated the expression of PD-L1, p-PI3K, p-AKT and upregulated the expression FOXO1.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pathogen free (SPF) BALB/c nude female mice (aged 5-6 weeks) injected with SK-BR-3 cells[1]
-
Dosage:200 μg
-
Administration:Three times a week; for 21 days
-
Result:Significantly inhibited tumor growth.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1.5X106 MDA-MB-231 cells labeling Adebrelimab (HY-P99422, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Immobilized HuPD-L1-hFc can bind Adebrelimab. The EC50 for this effect is 4.213 ng/mL.
化学情報
-
CAS 番号 2247114-85-6
-
性状 Liquid
-
分子量 145.56 kDa
-
Color Colorless to light yellow
-
SMILES
[Adebrelimab]
-
別名
SHR-1316
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)